ClearPath (@ClearPath100) profile picture

Particular focus on bio, fintech, deeptech and broader vertical AI themes.

Joined March 2025
Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)Photo by ClearPath (@ClearPath100)
ClearPath retweeted
this is pretty funny, and an on point description of the first day to first wk post event dynamics this fall, which are a bit of a mess. fortunately things seem to have started to improve.
You mean you don't appreciate when your biotech holding with fantastic data is up 40% in the premarket with 50% more upside to fair value, and then gets crushed to flat at open because risk at a large MM market sold a pod's holdings for blowing up on a MRNA short position, and then a quant momentum strategy shorts it because of the big pullback, and then a quant fund piles on the selling pressure by hedging their AI long trade by shorting interest rate risk out with a SMID cap biotech short, and then the stock is down 15% and no one knows why so an analyst publishes that obviously the stock is down because (pick random datapoint that doesn't matter) but in reality was just persuaded on a call with a pod PM to be bearish because they had a short position they needed to press and then that narrative gets entrenched and you're sitting here wondering why this company swung 60% down on great data and is financed through CF+ and trades at a big discount to some other biotech company and the world moves on to the next company with data tomorrow and no one cares to re-visit your company because it's a "catalyst desert" for 3 months? And pharma then passes over it and buys an undifferentiated pre-clinical private China asset instead of your company, which blows up on them a year later and they write it down but now your company needs to finance at a discount to the prior data? How could you not love that?
2
28
3,879
ClearPath retweeted
As some may say, there's a new Marshall in town
$qure $clpt Per @LogicalValueMx It’s time, it’s Marshall time.
1
20
2,556
TNG episode The Measure of a Man (Season 2, Episode 9) is a must see. The whole crew is at its finest.
142
The significance of $SPCX achievement can’t be emphasised enough, it represents a paradigm shift
After careful consideration, I feel hopeful for humanity again. 💙🚀
220
Do you believe now?
976
2,479
347
32,941
1,379,045
Mission accomplished
Mechazilla catches Starship! Congratulations to the entire SpaceX team on this incredible achievement!
191
ClearPath retweeted
Made on Earth by humans
6,061
18,155
1,459
227,743
7,277,054
CTA positioning. No comment
Nasdaq trend-followers have already cut exposure sharply. Our Q-CTA model shows NQ positioning at −0.91%, near its lowest levels in a year. Meanwhile, SPX is barely long at +0.51%. Systematic selling may be fading, but a sustained rebound could bring CTAs back.
1
270
$QURE: Useful commercial detail in Guggenheim’s Nov. 2 “Top Pick” note: -Physician checks identify ~24 US sites with intraoperative MRI and ClearPoint capability. Guggenheim envisages ~25 treatments/month during the first six months after launch, rising toward ~50/month in the second six. -The ~6,000 addressable symptomatic patients cited already account for striatal-volume requirements and some access barriers. -The note references a $2.5–4.0m pricing range, although an actual launch price remains unconfirmed. Guggenheim also views the planned AdCom as potentially constructive, expecting clinicians and patients to support AMT-130’s benefit–risk profile.
6
3
37
8,136
$ZURA did fairly extensive DD and ultimately decided to sit this one out, right decision in hindsight.
Interesting thesis, but $ZURA is a v risky one!
1
7
1,086
ClearPath retweeted
Biology is not just a Rube Goldberg Turing Machine but so much more, because when you look at what the molecules really are and how they push - why it's electric forces, and the chemical bonds are electronic too, and all these molecules and atoms are bathed in a common sea of electromagnetism that does not just travel fast rather it defines the speed of causality. And that these chemical bonds and molecular rotations all vibrate, DC electric fields wiggling into AC fields, and these AC fields travel as photons and land as phonons heating things up, making and breaking bonds, changing their shape, we feel this as heat, as light, and our bodies are made of towering stacks of electronic bonds each with its own energy level that are so closely spaced as to be continuous, and all these bonds and molecules vibrating and emitting and absorbing constitute a constant exchange of field energy and information with the towering stacks of electronic bonds in our surroundings, like tall ships with endless stories of cannons exchanging electromagnetic broadsides in both directions at once, at all times, along minimal paths in spacetime, at quantized energy levels. And you'd rightly think this is all wondrously mad and fantastical and surely just a mathematical model and I say no - this is sight, this is what it means to see, both literally and figuratively, to know that your experience is constituted by electromagnetic field interaction in its entirety, and these same fields are what planets, stars, everything is made of, and when you open two quarter sized holes in your head and let it all in this is what you *see*. The world as constructed in your mind, the surface of your retina coupled to the surface of the wall, a cloud, a distant galaxy by a field wiggling both ends at once. Now you consider all these things and what energy means, and how it flows through the body and the air and environment as a currency animating dead matter into life, that it comes from the Sun, ultimately, crushing protons into Helium and bathing the solar system in it's electromagnetic field of life giving energy, passed as photons and minted by chloroplasts into sugar, and if you really start to visualize and understand the true nature of what you're in, what the constituent building blocks of everyday experience actually turn out to be in the details, then you know for certain that humans are like children playing on the shore of an ocean so deep and wide as to make our greatest imagination and dreams seem shallow. And that the laws of nature are as much for our discovery as we are to be a discovery of the universe getting to know itself.
35
70
8
542
23,419
Indeed
Replying to @dannybuck
Environment is the biggest dictator of your standards
1
316
Read this!
here are some principles about neuroplasticity and how to apply it: 1. if it feels hard, it's working. your brain only changes when it's challenged enough to adapt. easy practice doesn't create the same changes in your neural pathways. 2. meaning accelerates learning. skills that feel relevant to your life are easier to learn and retain than those that don't. your brain pays more attention to things that actually matter to you. 3. a walk after studying is part of the work. exercise increases the release of a protein called BDNF, which supports the growth and strengthening of brain connections. 4. teach it to remember it. explaining something to someone else helps you remember it better than simply studying alone. 5. age slows neuroplasticity, but it never stops it. research shows that the brain can continue learning and forming new connections at every stage of life. 6. repetition is what makes it stick. every time you repeat something, you reinforce the neural pathways behind it.
1
330
$QURE’s Q3 call added several useful details beyond BLA acceptance and Priority Review. Four-year data: Management said FDA has not discussed requesting the four-year dataset to date. That is more reassuring than simply having no request publicly disclosed. Confirmatory study: The protocol has been submitted to US institutional review boards, with screening expected by year-end. Recruitment will extend across North America, Europe and Latin America, including countries where AMT-130 will not be commercially available during the study. That directly addresses the risk of control patients leaving to obtain treatment elsewhere. Sample-size planning also incorporates potential dropout. Launch capacity: Management anticipates more than 15 centres at launch, with 25–30 under consideration. Capacity varies substantially by institution, and the initial focus is on higher-throughput centres with existing HD expertise and ClearPoint capabilities. Manufacturing supply is not expected to be the constraint. Label assumptions: Commercial planning already assumes striatal-volume restrictions. A broader label could therefore provide upside to management’s market assumptions. Label discussions with FDA have not yet begun. Funding and pipeline: The projected runway into 2030 includes launch and confirmatory-study spending. All seven patients in the higher-dose epilepsy cohort have now been dosed, with results expected in H1 2027. This is incrementally positive, no doubt. The Q3 call also strengthens the practical case for getting through review, running the confirmatory study and delivering treatment after approval.
13
1,130
This is worth a read
The last few days are the brief, @davidellison. Patrick Stewart’s death did not produce a nostalgia spike. It showed that Picard still teaches people how to lead, how to listen, and how to hold a moral line without cruelty. That reach is rare. It is organic, it crosses age and politics, and it is not a campaign. People who agree on almost nothing still agree about Picard. The audience never left. The question for @Skydance @paramountplus @startrek is whether they build something worthy of that influence, or keep making shows that talk down to it.
1
261
$NBIS Nebius has customers (putting aside the hyperscaler anchor tenants) with very particular requirements. Many of them growing exceptionally fast, safe to say. The roster includes Revolut, Black Forest Labs, Higgsfield, and Prosus.
Nebius CTO, Danila Shtan, on the competitive field and compute capacity: "We are the AI cloud, we don't care, let other guys be neoclouds. We are the AI cloud and this is our mental model. We are not competing with the neocloud markets, we kind of believe we are past that. Our next competition point is taking on AWS and Google Cloud." "People are concerned that these investments are huge and people put a lot into the infrastructure, etc. My view, if I compare what we see in the market with what was there 2 years ago, we are barely scratching the surface. I think the overall demand over the next 3 years will increase 10 fold, 100 fold maybe." Via @jacobeffron $NBIS $AMZN $GOOGL
334
Great perspective on what the eventual approval of AMT-130, the first decease-modifying treatment for HD, means for patients and their families.
Huntington's disease has been passed from parent to child for as long as anyone has kept records, and medicine has never had a treatment that slows it. Today that could start to change. The FDA accepted uniQure's application for AMT-130, a one-time gene therapy for Huntington's, and gave it Priority Review. A decision is due by May 1, 2027. uniQure is a gene therapy company based in Amsterdam and Lexington, Massachusetts. The therapy is given once, through MRI-guided neurosurgery, directly into the striatum, the part of the brain the disease damages first. It carries a small piece of RNA that silences the huntingtin gene. In the Phase I/II study, patients on the high dose saw their disease progress 75% more slowly over three years on the main clinical scale than 940 closely matched patients from Enroll-HD, a natural history registry. Daily functioning declined 60% more slowly. Every child of a parent with Huntington's has a 50% chance of inheriting it. I've spent ten years building fertility companies, and for these families one of the few tools so far has been IVF with genetic testing of embryos, so the gene stops with them. That protects the next generation. It does nothing for the parent who already carries it. A therapy like this is the missing half. I also like how the evidence was built. The comparison came from years of data that patients and families gave to a registry, long before any drug existed. At Certuma we have met with the FDA too, and I've learned how much careful evidence like this moves a regulator. Congratulations to the uniQure team and to every family who joined these trials. For generations, a Huntington's diagnosis came with a known ending. Now there is a date on the calendar.
9
516
ClearPath retweeted
$QURE’s platform franchise era has officially begun. A 1 of 1 HD asset and more to come. Stay tuned.
7
4
91
10,199